As the pandemic wanes, for now, the ever-rising cost of health care is again taking center stage. Meanwhile, a year into the Biden administration, the FDA finally has a Senate-confirmed commissioner, Dr. Robert Califf. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Hannah Wesolowski of the National Alliance on Mental Illness, about how the pandemic has worsened the nation’s mental health crisis and what can be done about it.
Episode 3 is an exploration of the forces that brought uranium mining to the Navajo Nation, the harmful consequences, and the fight for compensation that continues today.
Congress is set to start its once-every-five-years review of the law that authorizes user fees to finance the hiring of personnel to speed the FDA review of drugs. The periodic renewals of “PDUFA” also give lawmakers a chance to make other changes to the agency at the hub of the pandemic. Meanwhile, the FDA could also find itself at the center of the abortion debate and a controversial new medication to treat Alzheimer’s disease. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
Health and Human Services Secretary Xavier Becerra is drawing criticism for his hands-off handling of the covid crisis even though the heads of the Centers for Disease Control and Prevention, National Institutes of Health, and FDA report to him. Meanwhile, the Department of Labor looks to enforce mental health “parity laws” that have failed to achieve their goals. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about a large emergency room bill for a small amount of medical care.
The No Surprises Act protects patients from surprise out-of-network bills. But there are caveats. For instance, these protections apply only to care in a hospital. This episode breaks it all down.
Native foodways of hunting, fishing, gathering, and farming have been under threat since the arrival of Europeans. In this episode, hear how Indigenous people are reclaiming their food traditions to improve community health.
Temporary subsidies helped boost enrollment under the Affordable Care Act to a record 14.5 million, according to the Department of Health and Human Services. But unless Democrats in Congress extend those subsidies, many of those new enrollees will be in for a rude surprise just ahead of midterm elections. Meanwhile, the need to replace retiring Supreme Court Justice Stephen Breyer further crowds an already tight legislative schedule. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet, and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Diana Greene Foster, author of “The Turnaway Study: Ten Years, a Thousand Women, and the Consequences of Having — Or Being Denied — An Abortion.”
Jan. 22 marks the 49th — and very likely last — anniversary of the Supreme Court’s landmark abortion decision, Roe v. Wade. The court’s conservative supermajority seems poised to overturn later this year the ruling that legalized abortion nationwide. Also this week, the Biden administration turns 1, with much of its domestic and health agenda yet unrealized. Alice Miranda Ollstein of Politico, Shefali Luthra of the 19th, and Kimberly Leonard of Insider join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Marjorie Dannenfelser, president of the Susan B. Anthony List, about what a post-Roe world might look like.
Explore what made the Navajo people ― also known as the Diné ― so vulnerable to the first surges of the covid-19 pandemic. The first episode of “Rezilience,” Season 4 of the “American Diagnosis” podcast, begins in the forests outside the Grand Canyon.
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.